Monoclonal antibodies as an immunotherapy of rheumatoid arthritis

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Rheumatoid arthritis(RA) is a chronic, deforming and destructive arthritis of unknown etiology. For the medical treatment of RA, NSAID has been the first choice of drug. Recently it has been known that early use of DMARD may result in clinical remission. Understanding of the pivotal role of cytokines and adhesion molecules for the rheumatoid joint destruction enabled us to target these cytokines and molecules as therapeutic measures. Monoclonal antibodies were produced against the cytokines and adhesion molecules such as IL-1, IL-6, IL-6R, TNF-alpha, as well as CD4 molecules. Clinical use of these monoclonal antibodies was found to be effective for rheumatoid arthritis. However these therapeutic measures have several disadvantages such as transient efficacy and side effect.

Original languageEnglish
Pages (from-to)776-781
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Volume56
Issue number3
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Immunotherapy
Rheumatoid Arthritis
Monoclonal Antibodies
Cytokines
CD4 Antigens
Antirheumatic Agents
Non-Steroidal Anti-Inflammatory Agents
Interleukin-1
Arthritis
Interleukin-6
Therapeutics
Tumor Necrosis Factor-alpha
Joints
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Monoclonal antibodies as an immunotherapy of rheumatoid arthritis. / Abe, T.; Takeuchi, Tsutomu.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 56, No. 3, 1998, p. 776-781.

Research output: Contribution to journalReview article

@article{e4467fa1a73f400c8accfb1c8941dff8,
title = "Monoclonal antibodies as an immunotherapy of rheumatoid arthritis",
abstract = "Rheumatoid arthritis(RA) is a chronic, deforming and destructive arthritis of unknown etiology. For the medical treatment of RA, NSAID has been the first choice of drug. Recently it has been known that early use of DMARD may result in clinical remission. Understanding of the pivotal role of cytokines and adhesion molecules for the rheumatoid joint destruction enabled us to target these cytokines and molecules as therapeutic measures. Monoclonal antibodies were produced against the cytokines and adhesion molecules such as IL-1, IL-6, IL-6R, TNF-alpha, as well as CD4 molecules. Clinical use of these monoclonal antibodies was found to be effective for rheumatoid arthritis. However these therapeutic measures have several disadvantages such as transient efficacy and side effect.",
author = "T. Abe and Tsutomu Takeuchi",
year = "1998",
language = "English",
volume = "56",
pages = "776--781",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "3",

}

TY - JOUR

T1 - Monoclonal antibodies as an immunotherapy of rheumatoid arthritis

AU - Abe, T.

AU - Takeuchi, Tsutomu

PY - 1998

Y1 - 1998

N2 - Rheumatoid arthritis(RA) is a chronic, deforming and destructive arthritis of unknown etiology. For the medical treatment of RA, NSAID has been the first choice of drug. Recently it has been known that early use of DMARD may result in clinical remission. Understanding of the pivotal role of cytokines and adhesion molecules for the rheumatoid joint destruction enabled us to target these cytokines and molecules as therapeutic measures. Monoclonal antibodies were produced against the cytokines and adhesion molecules such as IL-1, IL-6, IL-6R, TNF-alpha, as well as CD4 molecules. Clinical use of these monoclonal antibodies was found to be effective for rheumatoid arthritis. However these therapeutic measures have several disadvantages such as transient efficacy and side effect.

AB - Rheumatoid arthritis(RA) is a chronic, deforming and destructive arthritis of unknown etiology. For the medical treatment of RA, NSAID has been the first choice of drug. Recently it has been known that early use of DMARD may result in clinical remission. Understanding of the pivotal role of cytokines and adhesion molecules for the rheumatoid joint destruction enabled us to target these cytokines and molecules as therapeutic measures. Monoclonal antibodies were produced against the cytokines and adhesion molecules such as IL-1, IL-6, IL-6R, TNF-alpha, as well as CD4 molecules. Clinical use of these monoclonal antibodies was found to be effective for rheumatoid arthritis. However these therapeutic measures have several disadvantages such as transient efficacy and side effect.

UR - http://www.scopus.com/inward/record.url?scp=0032012743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032012743&partnerID=8YFLogxK

M3 - Review article

VL - 56

SP - 776

EP - 781

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 3

ER -